- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00672919
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. (COMPLEMENT)
A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy
Study Overview
Detailed Description
Diabetes mellitus is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes has a genetic predisposition, but lifestyle, physical habits and age play important roles in determining its time of onset and severity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic (liver) and peripheral-tissue cells to circulating insulin (ie, insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (ie, insulin deficiency due to beta-cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 15.7 million people have diabetes, with type 2 diabetes occurring in approximately 90 to 95% of cases.
Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes. Recently introduced drugs for diabetes therapy are the thiazolidinedione class. Thiazolidinediones increase glucose utilization, decrease gluconeogenesis and increase glucose disposal through an incompletely understood mechanism but one associated with binding of the drug to receptors known as peroxisomal proliferator-activated receptors.
Thiazolidinediones are peroxisomal proliferator-activated receptor agonists reducing insulin resistance in muscle cells, adipose (fat) tissue, and hepatic cells (inhibiting hepatic gluconeogenesis) with no direct impact on insulin secretion. Thus peroxisomal proliferator-activated receptor agonists improve glycemic control and result in reduced levels of circulating insulin. Peroxisomal proliferator-activated receptors are found in various tissues important for insulin action, with the greatest concentration of these receptors is in adipose tissue.
Pioglitazone is a peroxisomal proliferator-activated receptor agonist developed by Takeda Chemical Industries, Ltd. (Osaka, Japan).
Participation in this study is anticipated to be approximately 20 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Carolina, Puerto Rico
-
PoncE, Puerto Rico
-
-
-
-
Alabama
-
Birmingham,, Alabama, United States
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
Bellflower, California, United States
-
Burlingame, California, United States
-
Fresno,, California, United States
-
La Jolla, California, United States
-
Long Beach, California, United States
-
Pasadena, California, United States
-
-
Colorado
-
Arvada, Colorado, United States
-
-
Connecticut
-
Norwalk, Connecticut, United States
-
Waterbury, Connecticut, United States
-
-
Florida
-
Aventura, Florida, United States
-
Hollywood, Florida, United States
-
Jacksonville, Florida, United States
-
Miami, Florida, United States
-
N. Miami Beach, Florida, United States
-
Tallahassee, Florida, United States
-
West Palm Beach, Florida, United States
-
-
Georgia
-
Columbus,, Georgia, United States
-
-
Idaho
-
Idaho Falls, Idaho, United States
-
-
Illinois
-
Chicago Heights, Illinois, United States
-
-
Indiana
-
Evansville,, Indiana, United States
-
-
Iowa
-
Des Moines, Iowa, United States
-
-
Louisiana
-
Lafayette, Louisiana, United States
-
-
Massachusetts
-
Fall River, Massachusetts, United States
-
Waltham, Massachusetts, United States
-
-
Mississippi
-
Tupelo, Mississippi, United States
-
-
Missouri
-
Chesterfield, Missouri, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
Staten Island, New York, United States
-
-
North Carolina
-
Raleigh, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Centerville, Ohio, United States
-
Dayton, Ohio, United States
-
-
Oregon
-
Medford, Oregon, United States
-
-
Pennsylvania
-
Meadville, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
Rhode Island
-
Warwick, Rhode Island, United States
-
-
Tennessee
-
Chattanooga, Tennessee, United States
-
Morristown, Tennessee, United States
-
Murfreesboro, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Arlington, Texas, United States
-
Houston, Texas, United States
-
Midland, Texas, United States
-
San Antonio, Texas, United States
-
-
Utah
-
Ogden, Utah, United States
-
-
Virginia
-
Orange, Virginia, United States
-
Virginia Beach,, Virginia, United States
-
-
West Virginia
-
Man, West Virginia, United States
-
-
Wisconsin
-
Wausau, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with type 2 diabetes mellitus
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study
- Has been taking a stable dose of rosiglitazone for greater than 90 days prior to screening.
- Has a triglyceride level greater than 200 mg per dL but less than 1000 mg per dL.
- Has been taking a stable statin therapy for greater than 90 days prior to screening.
- Has a glycosylated hemoglobin less than 10.5%.
Exclusion Criteria:
- Type 1 diabetes mellitus.
- Treated with Gemfibrozil within 90 days of screening.
- Previous history of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug.
- The subject has an alanine aminotransaminase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.
- Male subjects who have serum creatinine greater than 2.0 mg per dL and female subjects with serum creatinine greater than1.8 mg per dL.
- Unexplained microscopic hematuria greater than plus 1 confirmed by repeat testing.
- Male subjects who have hemoglobin less than 10.5 g per dL and female subjects who have hemoglobin less than 10.0 g per dL.
- Significant cardiovascular disease including, but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV
- Currently is participating in another investigational study or has participated in an investigational study within the past 30 days.
- Any other serious disease or condition that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Glucocorticoids (eg. prednisone, cortisone, hydrocortisone, dexamethasone) with the exception of a topical glucocorticoid agent.
- Gemfibrozil
- Steroid-joint injections.
- Thiazolidinediones with the exception of the study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone QD
(and stable statin therapy)
|
Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Triglyceride Levels
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Total Cholesterol
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in direct Low Density Lipoprotein cholesterol
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in High Density Lipoprotein cholesterol
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in apolipoprotein B (apoB)
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in apolipoprotein A1 (apoA1)
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in Free Fatty Acids
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in Lipid Fractionation
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Change from Baseline in C-reactive Protein
Time Frame: Weeks 8 and 17 or Final Visit
|
Weeks 8 and 17 or Final Visit
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-03-TL-OPI-523
- U1111-1115-8914 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States